spacer
home > ebr > winter 2002 > beyond the patented genome: protecting discovery in the new biology estate space
PUBLICATIONS
European Biopharmaceutical Review

Beyond the Patented Genome: Protecting Discovery in the New Biology Estate Space

Intellectual property (IP) drives the pharmaceutical industry because making drugs is relatively cheap; discovering them, very expensive. IP protection is essential for any industry where the costs of innovation far exceed the costs of production. Figuring out what drug to make takes huge capital investment, but once the answer is known, it can be copied at relatively small marginal costs. Without IP incentives to drive the very high costs of drug discovery, no one could reasonably be expected to invest in the business for long. The traditional IP protection of pharmaceuticals is long-standing: the composition-of-matter patent, typically covering a particular genus of small molecule. Claims to particular species, methods of making and using the claimed compounds, and pharmaceuticals containing them, often round out the portfolio. Protection of therapeutic biologics has developed along similar lines. In general, protection of investments in the development of therapeutics has traditionally revolved around patent protection of the therapeutics themselves, the endpoints of discovery.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Arie M Michelsohn, PhD, JD, Member of the Bio/Pharmaceutical Practice Group at Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Dr Arie Michelsohn is a member of the Biotechnology/Pharmaceutical Practice Group at Finnegan, Henderson, Farabow, Garrett & Dunner, where he specialises in strategic counselling and patent infringement litigation in the areas of genomics, proteomics, bioinformatics and pharmaceuticals.
Dr Michelsohn has extensive experience in motion practice and discovery and has lectured and chaired several panel presentations on New Biology topics. He holds a JD from the George Washington University Law School and a PhD in Cellular and Molecular Biology from the California Institute of Technology. Dr Michelsohn is an active member of the Biotechnology Industry Organization. .

spacer
Dr Arie Michelsohn
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Advances in Aseptic Blow-Fill-Seal Processing of Pharmaceutical Liquids Improve Product Integrity and Patient Safety

Weiler Engineering, Inc

The latest improvements in aseptic blow-fill-seal technology are providing more streamlined automation of critical B/F/S processing areas, while limiting human intervention and effectively reducing airborne microbial bioburden and particulate levels, and enhancing sterility assurance and patient safety.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement